Actively Recruiting
Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study
Led by University Hospital Erlangen · Updated on 2024-10-15
380
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
Sponsors
U
University Hospital Erlangen
Lead Sponsor
R
Roche Diagnostics International AG
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.
CONDITIONS
Official Title
Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female subjects age 15-25 years
- Signed written informed consent
You will not qualify if you...
- Less than 1 year from onset of menarche
- Use of hormonal contraceptives
- Documented ongoing pregnancy
- Major ovarian abnormalities, including only one ovary, cysts, or solid masses larger than 2 cm detected by ultrasound
- Documented malignancy or current radiation therapy or chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Obstetrics and Gynecology, University Erlangen Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
Erlangen, Germany, 91054
Actively Recruiting
Research Team
L
Laura Lotz, Dr. med.
CONTACT
R
Ralf Dittrich, Prof.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here